Rice Hall James & Associates LLC Sells 35,684 Shares of LeMaitre Vascular, Inc. $LMAT

Rice Hall James & Associates LLC trimmed its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 16.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 178,186 shares of the medical instruments supplier’s stock after selling 35,684 shares during the period. Rice Hall James & Associates LLC owned approximately 0.79% of LeMaitre Vascular worth $15,593,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in LMAT. Advisors Asset Management Inc. raised its position in LeMaitre Vascular by 3.0% during the second quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier’s stock valued at $341,000 after purchasing an additional 118 shares in the last quarter. Federated Hermes Inc. increased its stake in shares of LeMaitre Vascular by 0.4% in the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock valued at $3,294,000 after purchasing an additional 155 shares during the last quarter. Johnson Investment Counsel Inc. raised its holdings in shares of LeMaitre Vascular by 0.7% during the 2nd quarter. Johnson Investment Counsel Inc. now owns 29,639 shares of the medical instruments supplier’s stock worth $2,462,000 after buying an additional 211 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of LeMaitre Vascular by 1.6% during the 2nd quarter. Franklin Resources Inc. now owns 13,499 shares of the medical instruments supplier’s stock worth $1,121,000 after buying an additional 212 shares in the last quarter. Finally, HighTower Advisors LLC lifted its position in shares of LeMaitre Vascular by 4.2% during the 1st quarter. HighTower Advisors LLC now owns 5,920 shares of the medical instruments supplier’s stock worth $497,000 after buying an additional 237 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Down 0.7%

LMAT opened at $83.78 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $105.55. The company’s 50 day moving average price is $86.00 and its two-hundred day moving average price is $87.25. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of 36.11, a PEG ratio of 2.09 and a beta of 0.68.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.05. The company had revenue of $61.05 million for the quarter, compared to analysts’ expectations of $62.18 million. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. LeMaitre Vascular’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. As a group, research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 4th. Investors of record on Thursday, November 20th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Thursday, November 20th. LeMaitre Vascular’s payout ratio is currently 34.48%.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Zacks Research raised LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. Wall Street Zen cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, December 6th. Barrington Research restated an “outperform” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Roth Capital reiterated a “buy” rating and set a $108.00 price target on shares of LeMaitre Vascular in a report on Wednesday, November 5th. Finally, Wells Fargo & Company cut their price objective on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.20.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.